Drawing for CLINIQAL

USPTO serial 85795273

CLINIQAL

Reviewed by CopyMark Law Group

Reg. 4586182Status 710
Filing date
Status date
Registration date
Aug 12, 2014
Examiner
ROACH, APRIL K
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with CLINIQAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Richard G. J. McDerby

RICHARD G. J. MCDERBY OSBORN MCDERBY LLP333 BUSH ST STE 2100SAN FRANCISCO, CA 94104-2817UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
035Performance assessment services in the fields of medical devices, biotechnology and pharmaceuticals namely evaluation of the business efficiency and business management of clinical research and clinical and medical laboratories; business consultation services in the field of procedure and policy implementation, approval process and monitoring practices and procedures, all relating to the conduct of clinical trials in accordance with client and regulatory authority guidance, laws and expectations; assessment of the progress of clinical trials and compliance with study protocols, policies, procedures and regulatory requirements, namely, providing independent business review of clinical trials; evaluating business processes, procedures and policies in relation to clinical trials in the fields of medical devices, biotechnology and pharmaceuticals; audit services in the field of clinical trials, namely, assessment of regulatory requirements, business practices and management in the field of biotechnology, pharmaceutical and medical device in relation to Good Clinical Practice guidelines; audit services in the field of clinical, medical and bioanalytical laboratories, namely, assessment of business practices and management in relation to Good Clinical Laboratory Practice guidelines; clinical data management process assessments, namely, providing independent business review of database management; audit of clinical investigators and investigational plans, namely, business auditing of business processes and database management of clinical trials conducted by clients; systems audits, namely, business audits; clinical research gap analyses and needs assessment analyses, namely, review of clinical trials for business purposes; business consulting in the field of protocols, policies and procedures for customers specializing in clinical trials; preparation of audit plans and checklists, namely, development and implementation of business audit plans for others; assessment of compliance with protocols, processes and internal controls, namely, providing independent business review of business management and operations of clinical trials for business purposes; assessment of compliance to existing practice guidelines, namely, business auditing; preparation of audit reports, namely, gathering and reporting information obtained through audits conducted for business purposes; pre-clinical to phase four clinical trial consulting services, namely, business auditing; business consulting and management in the field of clinical trials, namely, clinical data management on behalf of medical device, biopharmaceutical and biotechnology companies to assist them with clinical research and applications for drug approval; business consulting and management for medical device, biotechnology and pharmaceutical companies, namely, business consultation and management of infrastructure development projects; providing independent review of clinical trials for business purposes in the fields of medical devices, biotechnology and pharmaceuticalsSECTION 8 - CANCELLEDMar 1, 2007
041Educational services, namely, conducting seminars and classes in the field of operations and administration of clinical trials and medical research in the field of medical devices, medicine and medical treatments; educational services, namely, conducting seminars and classes in the field of operations and administration of clinical, medical and bioanalytical laboratories; education services, namely, providing custom designed training seminars and workshops in the field of clinical trials, clinical laboratories, medical laboratories, and bioanalytical laboratories; training clinical trial site personnel concerning drug protocol requirements and the use of tests and rating systems for such protocol; training clinical trial site personnel in the use of medical and research equipment required by drug protocols; providing training in the field of clinical trials and clinical trial management for the medical device, pharmaceutical and biotechnological industries; consultation services in the field of educational training in the field of conducting clinical trials in accordance with client and regulatory authority guidance, laws and expectations, and Good Clinical Practice regulatory mandates and guidelinesSECTION 8 - CANCELLEDMar 1, 2007
042Consultation services in the field of medical research and clinical trials in the pharmaceutical, biotechnology and medical device industries; consultation services for medical and scientific research purposes in the field of pharmaceutical and biotechnical investigation and human testing; clinical research program development services in the pharmaceutical, biotechnology and medical device industries; medical and scientific research consulting services, namely, consulting on clinical trials in the fields of pharmaceuticals, biotechnology, and medical devices; accreditation services, namely, developing, evaluating, and testing standards for clinical trials of pharmaceuticals, biotechnology and medical devices for the purpose of accreditation; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, Corrective and Preventive action follow -up and effectiveness verification, in the field of clinical trials, clinical research, medical laboratories, bioanalytical laboratories, and clinical laboratories for pharmaceuticals, biotechnology and medical device companies; providing quality assurance services in the field of pharmaceuticals, biotechnology and medical devices, namely, testing, analysis, and evaluation of clinical testing of pharmaceuticals, biotechnology, and medical devices; testing, analysis and evaluation of clinical testing of pharmaceuticals, biotechnology and medical devices to assure compliance with industry standards and regulations; consultation services in the field of monitoring practices and procedures for scientific research purposes relating to the conduct of clinical laboratories, medical laboratories, bioanalytical laboratories, and clinical trials in accordance with client and regulatory authority guidance, laws and expectations, good clinical and documentation practices; quality assurance services in the fields of medical devices, biotechnology and pharmaceuticals; clinical data management process assessments, namely, maintenance of software; assessment of compliance with protocols, processes and internal controls, namely, testing and evaluation of clinical trials of others to assure compliance with industry standards; assessment of compliance to existing practice guidelines, namely, evaluating clinical trials for accreditation purposesSECTION 8 - CANCELLEDMar 1, 2007
045Regulatory compliance consulting in the field of clinical trials; regulatory compliance consulting as it applies to the medical device, pharmaceutical, and biotechnology industries; tracking and monitoring regulatory requirements in the field of clinical trials, medical laboratories, clinical laboratories and bioanalytical laboratories for regulatory compliance purposes; reviewing standards and practices to assure compliance with clinical trial laws and regulations as applied to the medical device, pharmaceutical and biotechnology industries; regulatory affairs, namely, reviewing standards and practices to assure compliance with clinical trial laws and regulations; regulatory compliance consulting in the field of bioanalytical laboratories; business compliance consultation, namely, regulatory compliance consulting in the field of medical devices, pharmaceuticals, and bioanalytics; assessment of safe medication handling practices in accordance with Investigational New Drug Application federal regulations, namely, regulatory compliance consulting; assessment of compliance with clinical protocols, processes and internal controls, namely, regulatory compliance consulting in the field of clinical trials; assessment of compliance to existing practice guidelines, namely, regulatory compliance consulting in the field of business compliance with country and industry specific regulations in the field of clinical trialsSECTION 8 - CANCELLEDMar 1, 2007

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 19, 2021C8..CANCELLED SEC. 8 (6-YR)—
Aug 12, 2019REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Aug 12, 2014R.SRREGISTERED-SUPPLEMENTAL REGISTERYour mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application.
Jul 5, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 2, 2014ALIEASSIGNED TO LIE—
Jun 16, 2014CNTAAPPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER—
Jun 13, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 12, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 12, 2014ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
May 12, 2014GNS1NOTIFICATION OF SUBSEQUENT FINAL EMAILED—
May 12, 2014GNCFCONTINUATION OF FINAL REFUSAL E-MAILED—
May 12, 2014CNCFACTION CONTINUING A FINAL - COMPLETED—
Apr 18, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 17, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 17, 2014ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Oct 18, 2013GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Oct 18, 2013GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 18, 2013CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Sep 24, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 23, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 23, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 23, 2013GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 23, 2013GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 23, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 23, 2013DOCKASSIGNED TO EXAMINER—
Dec 15, 2012MPMKNOTICE OF PSEUDO MARK MAILED—
Dec 14, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 8, 2012NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance